BACKGROUND: Nonmetastatic, noninflammatory, invasive breast cancers with skin involvement (SI) are classified as T4b, regardless of size. This study evaluated disease-specific survival (DSS) to determine whether size should be considered for these lesions rather than grouping them all into stage III. STUDY DESIGN: Surveillance, Epidemiology, and End Results data linked to Medicare claims were reviewed.
Locally advanced breast cancers account for 5% to 10% of new breast cancer diagnoses in the United States and 60% to 70% of cases worldwide. According to the American Joint Committee on Cancer (AJCC) TNM classification (7th edition), breast cancer lesions with direct extension to skin beyond the dermis are considered locally advanced and grouped as T4b primaries.
Regardless of tumor size and involvement of regional lymph node basins, the presence of significant skin involvement (SI) places any tumor into stage III, 1 where
Disclosure Information: Nothing to disclose. 5-year overall survival ranges from 41% to 67%. 2 The TNM staging criteria were created to provide groupings for prognosis and treatment of patients with breast cancer. However, because the SI characteristic is the primary determinant for classification, overriding size and nodal status, the heterogeneity of the T4b category is significant. A paucity of data exist because of the low frequency of these tumors, however, if SI was not considered, earlier data suggest that nearly 60% of these tumors would be classified as T1 or T2, and 13% might be node negative. 3 A few small studies have analyzed patients with T4b tumors, however, they have all suggested that this subset of breast cancers has widely varied prognoses. [3] [4] [5] [6] [7] [8] Because cancer normally invades surrounding structures, logic suggests that a small invasive tumor that, by chance, arises close to skin and grows through it, does not necessarily have a worse prognosis than a similarly sized tumor arising and growing distant from skin. The lack of data, however, has prohibited any such assertion.
This study was performed to describe the diversity among noninflammatory breast cancers with SI that would be classified as T4b by using a large populationbased dataset to determine whether tumor size and nodal status should play a more prominent role in staging such lesions.
METHODS
Data were derived from the SEER-Medicare linked claims database with approval from the National Cancer Institute 9,10 and our institutional IRB. Although SEERMedicare linked data are limited to patients 65 years and older, they provide more specifics than SEER data alone about the surgical procedures, radiotherapy, and treatment dates. The SEER data provide no chemotherapy information and Medicare claims do.
Patients were included who were likely to have claims from 1 year before and after the SEER diagnosis month. Although patients were restricted to their first breast cancer, those with other earlier malignancies were not excluded. All 16 applicable SEER registries were used to increase the external generalizability of the results.
Included patients had a diagnosis of invasive breast cancer at 65 years of age or older from 1992 to 2005, and had cancer-directed surgery.
The SEER extent of disease (EOD) codes were used to identify confinement to breast tissue or involvement of skin or chest wall (see Table 1 for definitions) and SEER stage is consistent with these codes. The following subgroups with pertinent EOD codes were included in this analysis: those having no SI (EOD codes 10, 11, 13, 14, 15, 16, 17, and 18) and those having extensive SI (EOD codes 50, 51, and 52), fulfilling criteria for T4b classification. Patients having involvement of subcutaneous tissue and dermis (limited SI not extensive enough to be T4b, EOD codes 20, 21, 23, 24, 25, 26, 27, and 28) or both extensive SI and chest wall involvement (EOD code 60) were excluded for a more definitive comparison between distinct SI and non-SI subgroups. Patients having metastatic, inflammatory cancer, and chest wall or extra-axillary nodal involvement were also excluded ( Fig. 1) .
After the subgroups were established, SI tumors were regrouped with AJCC 7th edition classifications using tumor size and nodal involvement, but without considering the SI that classified these tumors as T4b; these reclassifications are referred to as "neostage." Patients having non-SI primaries were reclassified into the same neostage groupings using tumor size and nodal involvement for comparison, by updating to AJCC 7th edition classification from earlier staging classifications. Mean tumor size by SI group was compared within neostage using t-tests, adjusted for multiple comparisons using the Benjamini-Hochberg method.
Propensity scoreÀbased weighting was used to adjust for differences in the SI and non-SI groups. 11 This method has been used and described previously. 12, 13 The propensity score is the probability of being in the SI group within stage, generated from a logistic regression model, including potential confounders. Within each stage, each person's data were weighted by the inverse of the probability that the person was in their observed SI group. This is similar to survey weighting, and creates an adjusted population in which the distribution of confounding factors across SI groups is similar, thereby reducing the impact of confounding. Confounding factors, including age, race, sex, histology, grade, estrogen and progesterone receptor status (ER, PR), surgery, chemotherapy, and radiotherapy, were included in a logistic regression model for each neostage to estimate the probability of being in the SI group. Patients were excluded from the non-SI group (n ¼ 896 [ 10 Preoperative chemotherapy (between first breast-related doctor visit and surgery) and postoperative claims within 1 year were identified. Radiotherapy claims were identified within 1 year after surgery. Differences in treatment by SI group were examined using logistic regression with adjustment for neostage. Increases in chemotherapy use over time were evaluated with the Cochran-Armitage trend test. Charlson Comorbidity Index 14 was estimated from diagnosis codes using the method of Klabunde. 15, 16 Disease-specific survival (DSS) was the primary result. To account for competing risk of other causes of death, disease-specific mortality (DSM) was estimated within Paget disease (without underlying tumor) EOD 10þ (11, 13, 14, 15, 16, 17, 18) Confined to the breast tissue and fat, including nipple and/or areola EOD 10þ (11, 13, 14, 15, 16, 17, 18) Confined to the breast tissue and fat, including nipple and/or areola EOD 20þ (21, 23 Unknown if extension or metastasis *Also see Figure 1 under exclusions. EOD, extent of disease.
neostage using cumulative incidence estimators with bootstrap standard errors. The DSS was calculated as 1 À DSM. Covariate-adjusted DSM was estimated using propensity score weighting. Subdistribution hazard ratios were estimated for each neostage using Fine and Gray competing risks regression 17, 18 with propensity score weighting. Plots of DSS (1 À DSM) were based on cumulative incidence estimates accounting for death from other causes. Survival estimations were from the first therapeutic surgery date. 19 Patients remaining alive were censored as of December 31, 2006 . Statistical significance was set at p ¼ 0.05 (2-sided). Analyses were performed using SAS software (version 9.2, SAS Institute) and STATA software (release 12, Stata Corp, 2011).
RESULTS
Among breast cancer patients with significant SI diagnosed from 1992 to 2005, 924 remained after all exclusions ( Fig. 1 ). These patients were compared with 66,185 patients with non-SI tumors. Mean age was 78.8 years and 75.0 years for SI and non-SI patients, respectively. Male breast cancer patients accounted for 3.5% of the SI and 0.8% of the non-SI tumors, and a greater proportion of SI patients were African American, with cohort characteristics listed in (Table 3) . Mean (AESD) and median tumor sizes were 5.0 cm (AE2.8 cm) and 4.2 cm for SI primaries (interquartile range 1.0 to 2.4 cm) and 1.9 cm (AE1.3 cm) and 1.5 cm (interquartile range 3.0 to 6.5 cm) for non-SI primaries. Among SI patients, neostage T1 and T2 tumors accounted for 43.0% of cases, but 91.4% of the non-SI patients. Patients known to be ER negative and PR negative accounted for 15.6% of SI vs 12.1% of non-SI patients (p ¼ 0.0015). Within each neostage, mean tumor sizes were significantly larger for SI tumors than non-SI tumors (Table 3) .
There were 77.7% of SI and 26.6% of non-SI patients with positive nodes. The mean number of positive nodes (AESD) was 6.4 (AE6.1) for SI and 3.6 (AE4.4) for non-SI tumors (p < 0.0001). There were no positive nodes in 22.3% of SI cases (n ¼ 206), 1 to 3 positive nodes in 31.7% (n ¼ 293), 4 to 9 positive nodes in 28.6% (n ¼ 264), and !10 positive nodes in 17.4% (n ¼ 161). The proportion of patients having SI tumors in neostage IIA and IIB was lower than for non-SI tumors (p < 0.01), and the median number of positive nodes among those having positive nodes was similar between the 2 groups ( Table 3) . Conversion of original non-SI tumor stage to neostage (ie, updating to AJCC, 7th edition) changed the stage for 4,338 non-SI tumors (6.6%). In redistributing SI tumors using neostage reclassifications, 4.5% became neostage I, 38.4% became neostage II, and 57.0% became neostage III (Table 3) .
Mastectomy was performed on 51.4% of non-SI and 90.7% of SI tumors overall, with surgery as the sole treatment (no radiotherapy or chemotherapy) in 50.2% and 49.2% of SI and non-SI cases, respectively (p ¼ 0.52). Neostage I patients underwent breast-conservation surgery in 35.7% of SI and 57.4% of non-SI tumors (p ¼ 0.0045), and neostage II patients underwent breastconservation surgery in 10.1% of SI and 40.0% of non-SI tumors (p < 0.0001). Radiotherapy was added to breast-conservation surgery in 66.3% of SI and 75.3% of non-SI tumors (p ¼ 0.0537), and chemotherapy and radiotherapy were both administered to 16.5% of SI and 9.4% of non-SI tumors (p < 0.0001). Chemotherapy use increased from 10.4% in 1992 to 21.4% in 2005 (trend test, p < 0.0001). Treatment is summarized in Table 4 .
Survival is presented in Figure 2 and Table 5 . For the 924 patients with SI, the adjusted 5-year DSS was 95.8% for patients with restaged tumors now classified as neostage I, 90.3% for IIA, 82.3% for IIB, and 68.4% for IIIA, declining to 36.4% for IIIC patients. The 5-year DSS rates were similar to non-SI tumors restaged as neostage I, IIA, and IIB, respectively, but SI tumors restaged as neostage IIIA and IIIC had a far greater disparity in their DSS than their similarly restaged non-SI counterparts (p ¼ 0.023 and p < 0.001, respectively). Skin-involved tumors reclassified as neostage IIIA had DSS closer to non-SI tumors of neostage IIIC. Subdistribution hazard ratios calculated from competing risk regression for DSM for SI vs non-SI were not different for tumors of neostage I, IIA, and IIB, but were significantly elevated at 1.54 and 1.85 for neostage IIIA and IIIC, respectively (Table 5 ). In addition, competing risk regression models were performed to assess DSM for tumors receiving chemotherapy (SI vs non-SI) and not receiving chemotherapy (SI vs non-SI). For neostages I, IIA, and IIB, DSM was not different between SI and non-SI tumors receiving chemotherapy, and not different between SI and non-SI tumors not receiving chemotherapy. However, SI tumors had a higher mortality regardless of use or nonuse of chemotherapy as vs non-SI tumors for neostages IIIA and IIIC (data not shown).
DISCUSSION
The TNM classification system was designed to group tumors having similar prognoses and provides clarity for treatment and research. 2 Breast tumors with significant SI have been classified as T4b (and therefore stage III) since the first edition of the AJCC staging system, published in 1977, 20 irrespective of size. Skin involvement is most frequently a result of larger tumor infiltration of overlying skin, but tumors that would be classified as T2 (>2.0 to 5.0 cm) account for approximately half of them, and smaller lesions account for another 11.6%. The low frequency of tumors exhibiting substantial SI is one reason why this study, with 924 such patients, is the largest of its kind to date, with little change in the classification of these lesions during the past 36 years.
If staging is designed to group tumors of similar prognosis, then the data presented here suggest that the current classification of SI tumors diverges from this principle. Historically, breast carcinomas that were large, visible, and had invaded skin, had frequent nodal involvement on initial presentation. These classic cases constituted the majority of such breast carcinomas and were appropriately classified as advanced-stage lesions when the staging system was defined. As early as 1943, Haagensen and Stout 21 noted that dermal involvement with edema conferred a 5-year cure rate of 0 to 18.2%, although many of these cases would later be classified as inflammatory carcinoma. That same year, the physical signs of inoperability defined by Haagensen and Stout 22 were >10 cm, skin ulceration, skin edema, chest wall fixation, and axillary lymph nodes !2.5 cm in transverse diameter or fixed to chest wall or skin. A few of these still classify a tumor as "unresectable" to this day.
Our series notes that the characteristics and outcomes of tumors having SI are heterogeneous and can demonstrate DSS as high as 96% when stratified purely by tumor size and nodal status, similar to early-stage tumors having no SI, with hazard ratios for death that do not differ substantially from those without SI. Although SI tumors more commonly have adverse features, adjustment in our models demonstrates that these measurable features contribute, but the SI itself has less prognostic importance than current staging suggests. This finding is consistent with small series noting that some of these tumors are large and have no regional metastatic involvement. In 1981, Zucali and Kenda 23 demonstrated that among 66 patients, T4 tumors <3 cm had a better overall survival at 5 years than tumors of 3 to 5 cm (71.3% vs 34.7%). Similar results were obtained by Wieland and colleagues, 24 who noted that the 5-year survival rate for patients with T4b, N0 to N3 tumors <3 cm was 81% (95% CI, 65e97%), which was also consistent with the 36% to 80% 5-year survival rate range 25 for patients with all tumors classified as stage III at the time. 26 More recently, in 2005, Güth and colleagues noted that in 119 patients, SI for breast tumors 5.0 cm had no effect on DSS compared with controls of similar sizes, Values here represent each treatment independently, so differences between SI and non-SI tumors may be interdependent. For instance, differences reflected in radiotherapy may result in part from differences in surgical treatment, so radiotherapy administration by surgery type is also delineated. In contrast, outcomes in Table 5 adjust for all modalities combined. *As per NCI SEER-Medicare requirements, cells containing fewer than 11 individuals have been censored. BCS, breast conservation surgery; non-SI, no skin involvement; SI, skin involvement.
and recommended completely abandoning the use of SI in staging outside of inflammatory carcinoma. They updated their findings a year later with similar results.
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These outcomes are consistent with our demonstration of similar DSS between SI and non-SI lesions reclassified as neostage T2N0 (IIA) and T2N1 (IIB), but not for T2N2 (IIIA) or T2N3 (IIIC), where SI did confer a higher mortality. This is reinforced by our finding that only neostage IIIA and IIIC SI patients were at increased risk of DSM compared with non-SI patients of similar stage and treatment (ie, whether or not they had chemotherapy), suggesting that the increased risk is due to SI differences rather than from use or nonuse of systemic therapy. Duraker and colleagues 28 noted in a series of 180 patients that DSS for patients with "classic" clinical T4b signs and having adjuvant or neoadjuvant chemotherapy was considerably worse than for those who only had histologic SI. All of these data reinforce the notion that there might be prognostic importance to significant SI, but that this should be subordinate to tumor size and nodal metastases, and still be maintained as part of staging.
In our study, the early neostage tumors (neostages I to II) had overall survival similar to those without any SI, suggesting that the term locally advanced is misleading for these smaller SI lesions, as this incorrectly suggests a poor prognosis. We must also consider that the use of the surgical term unresectable, frequently used for any skin-involved lesion, might not be appropriate for all such lesions, as this connotes an inability to provide a surgical benefit when chemotherapy is not used. Data presented here contradict that by noting a low diseasespecific mortality, even when some lesions are resected in the absence of nonsurgical therapy. The multimodal standard of care for small SI lesions, the indications for which need to be refined, has traditionally been used for any lesion involving skin. This stems from the fact that SI lesions are more commonly large and have nodal involvement and benefit from such therapy.
Although inflammatory breast cancer has become a clear contraindication to breast conservation therapy 29 and extensive SI is also considered "unresectable," there remains no standard for the smaller T1 and small T2 skin-involved primaries. The benefit of neoadjuvant chemotherapy has not been scrutinized for such tumors, and there are no data to our knowledge that address which SI lesions might undergo breast conservation therapy alone without a compromise in outcomes. Studies of neoadjuvant chemotherapy for breast conservation still typically exclude any SI lesions and some maintain, even without evaluation, that breast conservation is contraindicated when SI exists from tumors of any size. 30 Although our data are retrospective, the multivariable adjustment that includes chemotherapy suggests that the smaller lesions might have a negligible benefit if SI is the sole adjuvant therapy indication. The lower frequency of such tumors, however, makes it unlikely that a prospective trial for such lesions will ever occur.
It is also difficult to infer a standard of care for small SI lesions because our data suggest that actual practice is Inflammatory and chest wall involvement excluded; SI reclassified. DSS, disease specific survival, estimated as 100% x (1 e cumulative incidence of disease-specific mortality); non-SI, no skin involvement; sHR, sub hazard ratio for breast cancer mortality, comparing risk of SI to non-SI, estimated using competing risk regression within each stage group; SI, skin involvement.
highly variable. Series in the literature that review the need for multimodal therapy for lesions deemed "unresectable" or "inoperable" typically include either few smaller SI lesions 31 or provide few or no details about the sizes of those primaries at presentation. 32, 33 We question the necessity of preoperative chemotherapy for the smallest of these lesions and believe that specific investigation is warranted if sufficient power could be achieved. Shen and colleagues 34 found that patients with SI breast tumors had a benefit from neoadjuvant chemotherapy by affording the ability to undergo breast conservation. These patients had a 5-year disease-free survival rate of 70%, but the median initial tumor size was 7.0 cm, and 67% had nodal metastases, limiting the applicability to this subset. Unfortunately, larger prospective trials, such as National Surgical Adjuvant Breast and Bowel Project, rigorously excluded patients with SI, making subset analysis impossible. [35] [36] [37] [38] In light of our findings, we believe that the addition of an SI category, analogous to the grade (G) category for sarcoma (TNMG), to refine the TNM stage should be considered. A tumor (T), node (N), metastasis (M), skin involvement (S) classification for breast cancers could allow for more homogeneous groupings than currently exist. For example, these data suggest that T1, N0, M0, S0 or S1 would remain stage I; and T1, N1, M0, S0, or S1 and T2, N0, M0, S0, or S1 would remain stage IIA. Although Güth and colleagues 5 suggested a more complex stratification for SI lesions, we do not believe that even our study, which is the largest of its kind, would have sufficient power to justify subdividing patients based on the extent of epidermal involvement, even if such data were available.
Our study is limited by its retrospective nature and the inaccuracies inherent to coding claims, as well as the limitations of registry data, including missing data, changes in coding standards, changes in expertise, and changes in staging. Although only 1.4% of tumors here were notable for SI, SEER-Medicare data are generalizable to the US population in this age group. 39 Younger age is poorly prognostic in breast cancer patients, but outcomes differences have not been significant enough to incorporate age into staging. Although this study evaluated only women 65 years of age and older, there is little to suggest that the relationship between women with and without SI would be different from younger women not analyzed here. Available treatment data are also limited by a lack of endocrine therapy data, but inclusion of receptor status should mitigate this. Although it is possible to assess outcomes from retrospective data, conclusions about variations in treatment cannot be definitively made without a prospective study.
CONCLUSIONS
Ultimately, these data suggest a need to consider revising the current TNM classification to allow for more uniform prognostic grouping of breast tumors. These findings demonstrate that outcomes are correlated with local tumor burden. Therefore, we recommend that consideration be given to classifying T4b (SI) tumors according to size and lymph node status, which will group them with lesions of similar prognosis, and add a staging descriptor to subclassify significant SI. Because it also appears that no current standard for treatment of small SI lesions exists, additional investigation might be warranted if a cohort of sufficient size can be garnered.
